Table 5.
Evolution of patients with gastrointestinal involvement treated with octreotide and bevacizumab.
| Patients | Gender | Age (Years) | VCE | Large (>3 mm) Telangiectases | >10 Telangiectases | Site | Before Treatment | Octreotide | Bevacizumab | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Follow-Up (m) | nº RBC | Follow-Up (m) | nº RBC | Dose | Follow-Up (m) | nº RBC | |||||||
| P.1 | Male | 68 | Yes | Yes | No | G-D-J | 66 | 11 | 21 | 4 | 10 mcg/m | - | - |
| P.2 | Male | 71 | Yes | Yes | No | G-D | 8 | 22 | 12 | 0 | 100 mcg/12 h | - | - |
| P.3 | Male | 55 | Yes | Yes | No | G-D | 38 | 8 | 3 | 1 | 20 mcg/m | - | - |
| P.4 | Male | 58 | No | No | No | G-D | 40 | 20 | 2 | 0 | 100 mcg/12 h | - | - |
| P.5 | Female | 55 | No | Yes | Yes | G-D-J-I | 21 | 9 | 16 | 3 | 30 mcg/m | - | - |
| P.6 | Male | 66 | Yes | No | Yes | G-D-J-I | 100 | >100 | 15 | 92 | 100 mcg/12 h | 21 | 3 |
| P.7 | Male | 51 | Yes | Yes | Yes | G-D-J-I | 74 | 93 | 6 | 12 | 100 mcg/12 h | 13 | 13 * |
| P.8 | Female | 51 | Yes | Yes | Yes | G-D-J-I | 36 | 36 | 9 | 5 | 10 mcg/m | - | - |
| P.9 | Male | 62 | Yes | Yes | Yes | G-D-J-I | 48 | 48 | 4 | 0 | 20 mcg/m | - | - |
VCE: video capsule endoscopy; G: Gastric; D: Duodenal; I: ileal; J: jejunal; m: month; nº RBC: number of units of packed red blood cells transfused before and during octreotide or bevacizumab treatments. * All during the first six months of bevacizumab treatment because of bevacizumab-induced hypertension and resulting severe epistaxis.